How have CYTHW shares performed in 2024?

Cyclo Therapeutics' stock was trading at $0.28 on January 1st, 2024. Since then, CYTHW stock has decreased by 10.7% and is now trading at $0.25. View the best growth stocks for 2024 here .

How do I buy shares of Cyclo Therapeutics?

Shares of CYTHW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CYTHW

Cyclo Therapeutics (CYTHW) Stock Price, News & Analysis

→ Gold Mania (From Stansberry Research) (Ad)

Free CYTHW Stock Alerts

$0.25

0.00 (0.00%)

(As of 05/3/2024 ET)

Compare

Today's Range: $0.25
▼
$0.25
50-Day Range: $0.22
▼
$0.31
52-Week Range: $0.13
▼
$0.50

Volume: 102 shs
Average Volume: 2,312 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get Cyclo Therapeutics alerts:

Ad Awesomely, LLC

Automatic Income (from home)

For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.

Just click here now to watch my presentation for free.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

CYTHW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYTHW Stock News Headlines

June 29, 2023 | businesswire.com

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol ® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

June 29, 2023 | finance.yahoo.com

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

See More Headlines

Receive CYTHW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: NASDAQ:CYTHW
CUSIP: N/A
CIK: 922247
Web: N/A
Phone: 386-418-8060
Fax: N/A
Employees: 8
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $1.08 million
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. N. Scott Fine (Age 67)
CEO & Director
Comp: $569.92k
Mr. C. E Strattan (Age 78)
Founder & Director
Mr. Joshua M. Fine (Age 42)
CFO & Secretary
Comp: $421.17k
Mr. Michael Eric Lisjak (Age 50)
Global Head of Regulatory Affairs & Senior VP of Business Development
Comp: $430.4k
Dr. Jeffrey L. Tate Ph.D. (Age 66)
COO, Chief Quality Officer & Director
Comp: $255.14k
Ms. Lori McKenna
Global Head of Patient Advocacy
Dr. Karen Mullen FFPM
Interim Chief Medical Officer

Key Competitors

View All Competitors

CYTHW Stock Analysis - Frequently Asked Questions

How have CYTHW shares performed in 2024?: Cyclo Therapeutics' stock was trading at $0.28 on January 1st, 2024. Since then, CYTHW stock has decreased by 10.7% and is now trading at $0.25.
View the best growth stocks for 2024 here.
How do I buy shares of Cyclo Therapeutics?: Shares of CYTHW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTHW) was last updated on 5/3/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial